Effects of a1-Blockers for Lower Urinary Tract Symptoms and @entity25 in @entity1 with XXXX .

@entity1 @entity1067 @entity3257 @entity2183 @entity25
OBJECTIVES: We evaluated the association of lower urinary tract symptoms (LUTS) and @entity25 ( @entity25 ) in @entity1 with @entity1067 ( @entity3257 ). We also examined improvement of @entity25 following the a1-blocker therapy for LUTS. METHODS: Sixty-eight male @entity1 were enrolled in the study, consisting of 38 cases with LUTS and @entity3257 ( @entity3257 group), and 30 @entity1 without significant LUTS or @entity3257 ( @entity3257 ). The degree of LUTS and @entity25 was evaluated by the International Prostate Symptom Score and the Pittsburg Sleep Quality Index (PSQI), respectively. The @entity1 of @entity3257 group then were treated with a1-blocker for 4 weeks, and were re-examined by all the questionnaires to evaluate the therapeutic efficacies. RESULTS: The correlation analyses showed a significant association of LUTS with @entity25 in @entity3257 group (r = 0.4995, P = 0.0068). Twenty cases (52.6%) in @entity3257 group showed 5.5 or more PSQI scores. Following 4 weeks of a1-blocker administration, the average PSQI decreased significantly from 6.3 to 4.8 points (P < 0.001). Significant improvement was observed in domains of " @entity25 " among PSQI (P = 0.0215 and 0.0391, respectively). Moreover, significant association between a1-blocker induced improvements of @entity2183 and @entity25 was identified in @entity1 with 5.5 or more PSQI score at baseline (r = 0.445, P = 0.0334). CONCLUSION: These results suggested that @entity25 is associated with LUTS among @entity3257 @entity1 and therapeutic effects of a1-blockers on LUTS lead to improvements of @entity25 .
